|
|
|
31.03.26 - 10:30
|
Semarion Secures $3.8 Million to Scale Next-Generation Cell Assay Technology and Accelerate Pharma Adoption (Business Wire)
|
|
|
Funding supports expansion of manufacturing and commercial capacity for SemaCyte microcarrier platformCAMBRIDGE, U.K.--(BUSINESS WIRE)--Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today announced it has raised $3.8 million USD (£2.9 million GBP). The fundraise was led by Parkwalk, and joined by The FSE Group, Cambridge Enterprise Ventures, Oxford Innovation Finance, Found Capital, Cambridge Capital Group, and Start Codon. The investment will facilitate commercial expansion and scale manufacturing of the Company's SemaCyte® platform which enables adherent cell models to be handled as assay-ready, barcoded reagents for more flexible, data-rich, scalable drug discovery.
With a growing pipeline of opportunities and strong industry interest, Semarion is focused on broad-scale customer adoption, strengthening partnerships and preparing for its next phase of growth. The funding will be...
|
|
|
|
|
|
|
08.01.26 - 12:06
|
EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology (Business Wire)
|
|
|
Proceeds advance multiple programs, including EPI-326 into first-in-human clinical trial in early 2026 for EGFR-driven lung cancer and head and neck cancerSAN MATEO, Calif.--(BUSINESS WIRE)--EpiBiologics, a leader in tissue-selective extracellular protein degradation, today announced the completion of a $107 million Series B financing co-led by GV (Google Ventures) and Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc (JJDC).
Novartis Venture Fund (NVF), Aulis Capital, Avego BioScience Capital, and Samsara BioCapital joined JJDC as new investors. In addition to GV, existing investors Polaris Partners, Digitalis Ventures, Taiho Ventures, Vivo Capital, Codon Capital, and Mission BioCapital participated in the round.
“We're delighted to work with this distinguished group of investors as we enter the next stage of EpiBiologics' growth. This financing allows us to advance our pipeline of novel bispecific antibodies to selectively degrade disea...
|
|
|
|
|
|
|
|
|
05.03.25 - 16:12
|
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases (Business Wire)
|
|
|
Oversubscribed financing led by Cambridge Innovation Capital and SV Health Investors' Dementia Discovery Fund with M Ventures and Pfizer Ventures joining
Investment will support further development of CNS penetrant therapeutics based on the Company's TRIMTAC™ aggregate-selective degraders
CAMBRIDGE, England--(BUSINESS WIRE)--TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, today announced the closing of its $31 million (£25 million) seed funding round. The financing was led by Cambridge Innovation Capital (CIC) and SV Health Investors' Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon.
The investment will support further development of the Company's growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggre...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
